Part 5 — Angiogenesis, Metabolic Adaptation & Expansion
How tumors in bone secure blood supply, survive hypoxia, and push deeper—designed for patients and researchers.
Note: The article body below is included exactly as provided—no deletions or edits—only structured and styled for readability. A summary table is included for quick scanning.
Angiogenesis, Metabolic Adaptation, and Expansion — In Simple Terms
Once cancer cells have settled in bone and set the stage with bone breakdown and niche remodeling, they need two big things to keep growing: a steady blood supply and a way to handle the stressful conditions inside bone marrow (like low oxygen and limited nutrients). This phase is about building new blood vessels, rewiring energy use, and pushing deeper into bone. Several genes and programs act together to make this happen.
The key players and what they do
| Gene / Program | What it is | What it does | Why it matters |
|---|---|---|---|
| VEGFA & HIF-1α | VEGFA signals vessel growth; HIF-1α is a hypoxia sensor. | Under low oxygen, HIF-1α induces VEGFA to sprout new, leaky vessels. | Brings oxygen/nutrients and waste routes so tumors can expand in bone. |
| HSP90AA1 | Chaperone that stabilizes stress-prone proteins (e.g., HIF-1α). | Keeps crucial signaling proteins folded and functional in harsh niches. | Enables multiple growth/survival programs to run simultaneously. |
| PI3K/AKT/mTOR | Master growth, metabolism, and stress-endurance pathway. | Optimizes energy use, supports protein synthesis and survival. | Provides stamina/fuel for expansion and death resistance. |
| MMPs | Matrix-cutting enzymes. | Carve space through bone/ECM and connect to vessels. | Allow deeper, wider infiltration; without them, growth is boxed in. |
* VEGFA and HIF-1α (drivers of new blood vessel growth)
Angiogenesis
- What they are:
- VEGFA is a signal that tells nearby cells to grow new blood vessels.
- HIF-1α is a sensor that turns on when oxygen is low (hypoxia), common in the crowded, marrow environment.
- What they do:
- When oxygen is scarce, HIF-1α becomes stable and switches on genes—including VEGFA—that promote the sprouting of new, leaky blood vessels toward the tumor.
- Why it matters:
- New vessels bring oxygen and nutrients and provide routes for waste removal, which allows the tumor to expand within bone.
* HSP90AA1 (chaperone dependence)
Stress support
- What it is:
- HSP90 is a “chaperone” protein that helps many other proteins fold correctly and stay active—especially stress-prone, cancer-driving proteins.
- What it does:
- In the harsh bone niche, cancer cells rely on HSP90 to keep crucial signaling proteins (like HIF-1α and others) stable and functional.
- Why it matters:
- This “chaperone dependency” lets cancer cells maintain multiple growth and survival pathways at once despite stress.
* PI3K/AKT/mTOR (integrated growth, survival, and motility)
Growth & metabolism
- What it is:
- A master control pathway that helps cells grow, divide, move, and endure stress.
- What it does:
- It adjusts metabolism so cells can make energy efficiently, even when nutrients are limited, and supports protein synthesis and survival under pressure.
- Why it matters:
- This pathway gives cancer cells the stamina and fuel to keep expanding in the bone environment and resist cell death.
* MMPs (continued local invasion)
Invasion
- What they are:
- Matrix metalloproteinases—enzymes that cut through the tissue mesh (extracellular matrix).
- What they do:
- Keep carving space in the bone and marrow, allowing the tumor mass to spread and connect with new blood vessels.
- Why it matters:
- Without these “molecular scissors,” growth would be boxed in; with them, the tumor can infiltrate deeper and wider.
The feedback loops that make things worse
- Hypoxia stabilizes HIF-1α, increasing VEGF
- As the tumor grows, oxygen runs low.
- Low oxygen stabilizes HIF-1α, which boosts VEGFA production.
- More VEGF means more new blood vessels, which feed further growth—until growth again outpaces supply, preserving the hypoxia–VEGF cycle.
- TGF-β remains a central amplifier
- Bone breakdown releases TGF-β from the matrix.
- TGF-β turns up genes that promote invasion (MMPs), homing/retention (CXCR4), and niche shaping (JAG1), and can interact with metabolic and angiogenic programs.
- This keeps the pro-metastatic program “loud,” reinforcing multiple steps at once.
A simple story of what happens
1. Running out of oxygen:
- As cancer cells multiply in the tight spaces of bone, oxygen gets scarce.
- The oxygen sensor (HIF-1α) flips on and tells the cells to adapt their metabolism and call for help.
2. Calling for blood supply:
- Cells release VEGFA—like sending out a distress flare—to pull in new blood vessels.
- New, fragile vessels grow toward the tumor, delivering oxygen and nutrients.
3. Staying functional under stress:
- The environment is tough: low oxygen, shifting nutrients, immune pressure.
- HSP90 keeps key proteins working, and PI3K/AKT/mTOR manages energy and growth so cells can keep going.
4. Making room to grow:
- MMPs cut through the surrounding bone and tissue mesh so the tumor can physically expand and reach those new blood vessels.
5. The cycle keeps turning:
- Growth causes more areas of low oxygen, which boosts HIF-1α and VEGF again.
- Ongoing bone resorption keeps releasing TGF-β, which ramps up invasion and niche remodeling.
- The tumor becomes more entrenched and expansive.
Why this phase is critical
- It transforms small, hidden colonies into larger, symptomatic tumors:
- New blood vessels and metabolic rewiring turn dormancy or tiny foci into growing metastases that cause pain, fractures, and other complications.
- It provides multiple vulnerabilities—but they interact:
- Blocking one piece (like angiogenesis) can help, but other pathways (like PI3K/AKT/mTOR or HSP90) may compensate.
- The most effective strategies often target more than one node or combine with earlier interventions (e.g., reducing bone resorption to lower TGF-β release).
Where this process could be interrupted (conceptually)
- Cut the blood supply (anti-angiogenesis):
- Lowering VEGF signaling reduces the tumor’s ability to build new vessels—starving the tumor of oxygen and nutrients.
- Blunt the hypoxia response:
- Reducing HIF-1α stability or activity lowers the emergency growth programs and VEGF output.
- Disrupt stress support:
- Weakening HSP90 support can destabilize multiple cancer-promoting proteins at once.
- Dampen growth and survival signals:
- Turning down PI3K/AKT/mTOR reduces the tumor’s ability to manage energy, make proteins, and resist death under stress.
- Limit local invasion:
- Reducing MMP activity curbs the tumor’s ability to carve out space and connect to new vessels, slowing expansion.
In short
Low oxygen in bone marrow stabilizes HIF-1α, which ramps up VEGF to grow new blood vessels.
HSP90 keeps fragile but important cancer proteins working under stress.
PI3K/AKT/mTOR is the engine room, managing energy and growth so cells can thrive in harsh conditions.
MMPs are the cutting tools that let the tumor physically expand and link to its new blood supply.
TGF-β continues to act like an amplifier in the background, turning up invasive and niche-remodeling genes, which keeps the whole system running.
Tackling this stage often means hitting more than one target: starving the tumor (anti-angiogenesis), dulling its stress adaptations (HIF-1α/HSP90/PI3K-mTOR), and limiting its ability to carve and spread (MMPs).
© 2025 Art of Healing Cancer · Educational content only; not medical advice.